FREQUENTLY ASKED QUESTIONS FOR
HEALTHCARE PROVIDERS


References:

  1. NDA 213872.

  2. Astepro. Prescribing information. Meda Pharmaceuticals Inc; 2018.

  3. US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed April 7, 2022. https://www.fda.gov/media/100100/download

  4. Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014.

  5. van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(5):512-518. doi:10.2500/aap.2009.30.3284

  6. Watts AM, Cripps AW, West NP, Cox AJ. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Front Pharmacol. 2019;10:294:1-22. doi:10.3389/fphar.2019.00294

  7. Flonase® Drug Facts Label. NDA205434.

  8. Nasacort® Drug Facts Label. NDA020468.

  9. Rhinocort® Drug Facts Label. NDA020746.

  10. Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Ecacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009:30(6):628-633. doi:10.2500/aap.2009.30.3296

  11. Data on file. Bayer. MP436 CSR. Safety and tolerability.